Everolimus-induced pneumonitis in patients with neuroendocrine neoplasms: real-world study on risk factors and outcomes
AuthorsTaboada, R. G.
Riechelmann, R. P.
Hubner, Richard A
McNamara, Mairead G
Valle, Juan W
AffiliationDepartment of Medical Oncology, A.C.Camargo Cancer Center, São Paulo, Brazil
MetadataShow full item record
AbstractBackground: Everolimus-induced pneumonitis (EiP) has been poorly studied in patients with neuroendocrine neoplasms (NEN) outside clinical trials. The aim of this study was to evaluate the incidence, risk factors, and outcomes of EiP in patients with NENs using real-world data. Methods: Retrospective study of everolimus-treated patients with advanced NENs. Imaging reports were systematically reviewed for the presence of pneumonitis. Clinical features and treatment profiles for EiP were summarized. Overall survival (OS) was calculated from the initiation of everolimus to the date of death or last follow-up using the Kaplan-Meier method. Results: A total of 122 patients were included. Median age at start of everolimus was 62 (19-86) years, 62% (76/122) were male, and half were from pancreatic origin (62, 51%). Twenty-eight patients (23%) developed EiP: 82% grade (G)1 or G2, 14% G3 and 4% G4. The median time to EiP was 3.6 (0.8-51) months. Primary tumor site, concurrent lung disease, smoking history, and prior therapies were not associated with the onset of EiP. Patients who developed EiP had longer time on everolimus treatment (median 18 months vs 6 months; P = .0018) and OS (77 months vs 52 months; P = .093). Everolimus-induced pneumonitis was a predictor of improved OS by multivariable analysis (HR 0.39, 95% CI 0.19-0.82; P = .013). Conclusion: Everolimus-induced pneumonitis in the real-world clinical setting is present in one quarter of patients with NENs receiving everolimus and often occurs early. While risk factors for EiP were not identified, patients with EiP had improved survival.
CitationTaboada RG, Riechelmann RP, Mauro C, Barros M, Hubner RA, McNamara MG, et al. Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. Vol. 27, The Oncologist. Oxford University Press (OUP); 2022. p. 97–103.
- Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs.
- Authors: Fehrenbach U, Rodríguez-Laval V, Jann H, Fernández CMP, Pavel M, Denecke T
- Issue date: 2021 Aug
- Interstitial pneumonitis caused by everolimus: a case-cohort study in renal transplant recipients.
- Authors: Baas MC, Struijk GH, Moes DJ, van den Berk IA, Jonkers RE, de Fijter JW, van der Heide JJ, van Dijk M, ten Berge IJ, Bemelman FJ
- Issue date: 2014 May
- Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
- Authors: Penttilä P, Donskov F, Rautiola J, Peltola K, Laukka M, Bono P
- Issue date: 2017 Aug
- The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
- Authors: Liu CT, Chen MH, Chen JS, Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chou WC, Chen YY
- Issue date: 2016 Dec
- Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.
- Authors: Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH
- Issue date: 2016 Jan